Some research has shown that dividend-paying stocks significantly outperformed their non-dividend-paying peers over the past ...

While Pfizer recently pulled the plug on its most advanced obesity candidate, Amgen has moved its own key weight loss play ...

Analysts highlight MariTide's upcoming updates and near-term catalysts, while Amgen's price targets shift amid steady outlook ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Amgen's diverse portfolio ensures stability, but risks like high debt and biosimilar competition loom. Check out my look at ...

The FDA has freed Amgen’s mysterious early-stage obesity asset from a clinical hold, with the phase 1 study now enrolling ...

Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations. MariTide (maridebart ...

Like fellow Big Pharmas Eli Lilly and Johnson & Johnson, Amgen is urging the Trump administration to consider tax policy ...

Amgen on Thursday said its first-quarter profit rose 24%, driven by product sales, and said that while it is premature to ...

Amgen's strategic growth through M&A and R&D ... The development portfolio also includes MariTide in obesity, Tarlatamab in oncology, and Olpasiran for reducing cardiovascular risk.

Sales of the company’s copycat to J&J’s blockbuster reached $150 million in the first quarter, adding to a surge in revenue ...

Amgen is an innovative leader in an industry ... The company has been working on a promising weight management candidate, MariTide. Though this product somewhat disappointed in phase 2 studies ...